CN105254502A - New diterpenoid compound and preparation method and medical application thereof - Google Patents
New diterpenoid compound and preparation method and medical application thereof Download PDFInfo
- Publication number
- CN105254502A CN105254502A CN201510830702.7A CN201510830702A CN105254502A CN 105254502 A CN105254502 A CN 105254502A CN 201510830702 A CN201510830702 A CN 201510830702A CN 105254502 A CN105254502 A CN 105254502A
- Authority
- CN
- China
- Prior art keywords
- compound
- cell
- preparation
- extract
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses new diterpenoid compound and a preparation method and medical application thereof. The compound is reported for the first time, is novel in structure and can be obtained by conducting extracting, separating and purifying dried mature fruit of fructus alpiniae oxyphyllae. It is proved through in-vitro tests that the compound can restrain proliferation of gastric carcinoma cells and promote apoptosis of gastric carcinoma cells, the growth restraining effect of gastric carcinoma cells is improved as the increase of the concentration, and the compound can be developed into medicine for treating gastric carcinoma.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to from the dry mature fruit of Sharpleaf Galangal Fruit, be separated obtain a kind of and there is diterpenoids compound for the treatment of Effect on Gastric Cancer and preparation method thereof.
Background technology
Sharpleaf Galangal Fruit is the dry mature fruit of Zingiber Alpinia plants intelligence development AlpiniaoxyphyllaMiq., is mainly distributed in the ground such as the Guangxi of China, Hainan, Guangdong.Sharpleaf Galangal Fruit is one of integration of drinking and medicinal herbs conventional Chinese medicine, and Sharpleaf Galangal Fruit is just as tcm clinical practice medicinal herbs most in use since ancient times, and all on the books in Ancient Times in China numerous medicine monograph, it is warm in nature, and taste is pungent, has warm kidney controlling nocturnal emission with astringent drugs contracting urine, the warming spleen and stopping diarrha function taking the photograph saliva.
Up to the present, from Sharpleaf Galangal Fruit, be separated the type of compounds obtained mainly contain sesquiterpenoids, monoterpenes, diterpenes, diphenyl heptane class, flavonoid, simple aromatics and fatty compounds.Sesquiterpene is the characteristic chemical composition in Sharpleaf Galangal Fruit, and its framework types, based on Airy not phenol alkane, eucalyptus alkane and cadinane type sesquiterpene or fall sesquiterpene, in addition, still has guainane, stichopus japonicus ketone and humulane type sesquiterpene.Sharpleaf Galangal Fruit has special fragrance, and this is that monoterpene is the chief component of its volatile oil owing to wherein containing abundant volatile oil.
In recent years about the pharmacological research of Sharpleaf Galangal Fruit mainly concentrate on extract and chemical composition neuroprotective, improve in ability of learning and memory, anti-oxidant, anti-ageing, antitumor, anti-inflammatory, antianaphylaxis and anti-stress etc.
Summary of the invention
The object of this invention is to provide and a kind ofly from the dry mature fruit of Sharpleaf Galangal Fruit, be separated obtain a kind of there is diterpenoids compound for the treatment of Effect on Gastric Cancer and preparation method thereof.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
There is the compound (I) of following structural formula,
The preparation method of described compound (I), comprise following operation steps: the dry mature fruit of (a) Sharpleaf Galangal Fruit is pulverized, extract with 80 ~ 90% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 15% ethanol elution, 8 column volumes, then use 75% ethanol elution, 12 column volumes, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract; C in () step (b), 75% ethanol elution thing medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 85:1,55:1,35:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 20:1,15:1 and 10:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 80%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
Further, in step (a), extract with 85% alcohol heat reflux, united extraction liquid.
Further, described macroporous resin is AB-8 type macroporous adsorbent resin.
A kind of pharmaceutical composition, this pharmaceutical composition contains the compound according to claim 1 (I) for the treatment of significant quantity and pharmaceutically acceptable carrier.
The application of described compound (I) in the medicine of preparation treatment cancer of the stomach.
The application of described pharmaceutical composition in the medicine of preparation treatment cancer of the stomach.
When the compounds of this invention is used as medicine, directly can uses, or use with the form of pharmaceutical composition.
This pharmaceutical composition contains the compounds of this invention (I) for the treatment of significant quantity, and all the other are acceptable on pharmacology, nontoxic to humans and animals and pharmaceutically acceptable carrier of inertia and/or vehicle.
Described pharmaceutically acceptable carrier or vehicle are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation assistant agent.Pharmaceutical composition of the present invention is used with the form of per weight dose.Medicine of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, dripping pill, micropill, suspensoid, emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into water-based or oily solution, aseptic powder injection, liposome or the emulsion etc. of sterilizing.
Accompanying drawing explanation
Fig. 1 is compound (I) structural formula;
Fig. 2 is that the theoretical ECD value of compound (I) compares with experiment ECD value.
Embodiment
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Embodiment 1: compound (I) is separated preparation and structural identification
Reagent source: ethanol, sherwood oil, ethyl acetate, propyl carbinol, methylene dichloride are analytical pure, purchased from Shanghai Ling Feng chemical reagent company limited, methyl alcohol, analytical pure, purchased from Jiangsu Han Bang chemical reagent company limited.
Preparation method: the dry mature fruit (8kg) of Sharpleaf Galangal Fruit is pulverized by (a), (25L × 3 time) are extracted with 85% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste (3L), use sherwood oil (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated propyl carbinol (3L × 3 time) to extract successively, obtain petroleum ether extract, acetic acid ethyl ester extract (347g) and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract AB-8 type macroporous resin removal of impurities in (b) step (a), first use 15% ethanol elution, 8 column volumes, use 75% ethanol elution, 12 column volumes again, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract (131g); C in () step (b), 75% ethanol elution medicinal extract purification on normal-phase silica gel is separated, successively with volume ratio be 85:1 (8 column volumes), the methylene chloride-methanol gradient elution of 55:1 (8 column volumes), 35:1 (6 column volumes), 15:1 (8 column volumes) and 1:1 (5 column volumes) obtains 5 components; D component 4 (29g) is separated further by purification on normal-phase silica gel in () step (c), successively with volume ratio be 20:1 (8 column volumes), the methylene chloride-methanol gradient elution of 15:1 (10 column volumes) and 10:1 (6 column volumes) obtains 3 components; E in () step (d), component 2 (11g) reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 80%, collect 8-10 column volume elutriant, elutriant concentrating under reduced pressure obtains pure compound (I) (33mg).
Structural identification: HR-ESIMS shows [M+Na]
+for m/z513.2506, can obtain molecular formula in conjunction with nuclear-magnetism feature is C
27h
38o
8, degree of unsaturation is 9.Hydrogen nuclear magnetic resonance modal data δ
h(ppm, DMSO-d
6, 500MHz): H-1 (2.49, t, J=13.5), H-1 (1.55, dd, J=13.5, 3.5), H-2 (2.56, m), H-3 (5.67, t, J=5.0), H-4 (2.11, dd, J=11.5, 5.0), H-5 (4.87, dd, J=11.5, 5.0), H-7 (1.78, ddd, J=15.5, 12.5, 2.0), H-7 (1.23, m), H-8 (1.93, m), H-8 (1.52, t, J=12.5), H-9 (3.39, dd, J=9.5, 4.5), H-11 (2.55, d, J=2.5), H-12 (4.19, d, J=2.5), H-16 (1.07, d, J=7.5), H-17 (0.70, s), H-18 (1.04, s), H-19 (0.51, s), H-20 (0.70, s), H-2 ' (8.06, d, J=7.0), H-3 ' (7.42, t, J=7.0), H-4 ' (7.54, t, J=7.0), H-5 ' (7.42, t, J=7.0), H-6 ' (8.06, d, J=7.0), 5-OH (4.03, d, J=5.0), 9-OH (3.55, d, J=4.5), 11-OH (5.37, s), 12-OH (5.37, s), 15-OH (4.75, s), carbon-13 nmr spectra data δ
c(ppm, DMSO-d
6, 125Hz): 42.1 (CH
2, 1-C), 35.9 (CH, 2-C), 78.2 (CH, 3-C), 54.4 (CH, 4-C), 64.0 (CH, 5-C), 49.6 (C, 6-C), 32.3 (CH
2, 7-C), 29.7 (CH
2, 8-C), 80.0 (CH, 9-C), 38.5 (C, 10-C), 59.3 (CH, 11-C), 57.1 (CH, 12-C), 56.6 (C, 13-C), 208.2 (C, 14-C), 85.5 (C, 15-C), 16.3 (CH
3, 16-C), 18.7 (CH
3, 17-C), 25.4 (CH
3, 18-C), 11.8 (CH
3, 19-C), 10.2 (CH
3, 20-C), 131.2 (C, 1 '-C), 130.0 (CH, 2 '-C), 128.8 (CH, 3 '-C), 133.4 (CH, 4 '-C), 129.1 (CH, 5 '-C), 130.2 (CH, 6 '-C), 167.1 (C, 7 '-C), carbon atom mark is see Fig. 1.Infrared spectra shows that this compound contains hydroxyl (3582,3500 and 3377cm
-1), carbonyl (1707 and 1687cm
-1) and aromatic ring (1603 and 1497cm
-1) group.
1this compound of HNMR spectrum display contains a benzoyl moiety at δ H8.06 (2H, d, J=7.0Hz, H-2 ' and H-6 '), 7.54 (1H, t, J=7.0Hz, H-4 ') and 7.42 (2H, t, J=7.0Hz, H-3 ' and H-5 '); Five containing oxygen methyne δ H5.67 (t, J=5.0Hz, H-3), 4.87 (dd, J=11.5 and 5.0Hz, H-5), 4.19 (d, J=2.5Hz, H-12), 3.39 (dd, J=9.5Hz and 4.5Hz, H-9) and 2.55 (d, J=2.5Hz, H-11); Five methyl δ H1.07 (d, J=7.5Hz, H
3-16), 1.04 (H
3-18), 0.70 (6H, H
3-17 and H
3-20) and 0.51 (H
3-19).Except benzoyl moiety,
13cNMR and DEPT composes display 20 carbon signals, also comprises five quaternary carbons (carbonyl carbon δ C208.2 and containing oxygen carbon δ C85.5) except the functional unit that correspondence is above-mentioned.In a word, these spectroscopic datas show that this compound is a diterpene alcohol benzoate compounds.In HMBC spectrum, H
2-1 and C-2, C-3, C-4, C-15 and C-16; H-3 and C-1, C-15, and C-7 '; H
3-16 and C-1, C-2 and C-3; The dependency of OH-15 and C-4 and C-14, and in conjunction with the chemical shift of these protons with resonance carbon, show that this compound contains the five-ring that is connected with methyl and benzoyl fragment, and C-15 position is connected with an oh group.H-4 and C-5 and C-6 in being composed by HMBC; H-5 and C-3, C-4, C-6 and C-17; H
3-17 and C-5, C-6 and C-13; H
3-20 and C-6, C-13 and C-14; OH-5 and C-4, C-5 and C-6; The dependency of OH-15 and C-14, known pimelinketone ring is connected with five-ring by C-4 with C-15, and C-5 position is connected with a hydroxyl, C-6 and C-13 position is connected with two tertiary methyl.In addition, H-9 and H-11 and C-18 and C-19; H-11 and C-12 and C-13; H-12 and C-13 and C-20; H
3-17 and C-7; H
3-18 and H
3-19 and C-9, C-10 and C-11; H
3-20 and C-12; With the dependency of C-10, OH-9 and C-9 shows that octatomic ring is connected with six-ring by C-6 with C-13, C-9, C-11, and C-12 position is respectively connected with a hydroxyl, and C-10 position is connected with two methyl.In NOESY spectrum, H-5 and H-12 and OH-15; H-12 and H
3the dependency of-19 shows that they are beta comfiguration.In addition, H-3 and H-2, H-4 and OH-5; H-4 and H-2, H-3 and H
3-17; H-9 and H-11 and H
3the dependency of-18 shows that these protons are α configuration.Comprehensive hydrogen spectrum, carbon spectrum, HMBC spectrum and NOESY spectrum, and document is about correlation type nuclear magnetic data, can substantially determine this compound as shown in Figure 1, steric configuration is determined further by ECD test, theoretical value and experimental value basically identical (Fig. 2).
Embodiment 2: compound (I) pharmacological action is tested
One, material and instrument
Human stomach cancer cell line SGC-7901 is purchased from Sai Er Reagent Company.Compound (I) is made by oneself, and HPLC normalization method purity is greater than 98%.PDTC, trypsinase, MTT, dimethyl sulfoxide (DMSO) (DMSO), agarose, Glacial acetic acid are purchased from Sigma Co., USA.RPMI-1640 substratum, PBS phosphate buffer soln are purchased from GIBCO company of the U.S..Foetal calf serum is purchased from Shandong Yin Xiang great achievement company.Trypan blue (Beijing Bioisystech Co., Ltd of Zhong Shan Golden Bridge), TUNEL test kit (Kai Ji biotechnology Development Co., Ltd), DAB colouring reagents box (Beijing biotech firm of Zhong Shan Golden Bridge), formaldehyde (Fisher company of the U.S.), catalase (new fine chemistry industry development centre, sky, Tianjin).
WD-9403C uv analyzer (German Biometra company), grads PCR instrument (German Biometra company), Labworks image acquisition and analysis software (Shanghai Tian Neng company), electrophoresis apparatus (Beijing 6 1), electronic balance (Shanghai precision instrumentation company limited), RKI-1002 type CO2gas incubator (Japanese Ikemoto company), Bechtop (Suzhou purification experimental installation company limited), ultracentrifuge (Beijing medical apparatus and instruments factory), low speed centrifuge (Beijing medical apparatus and instruments factory), WilovertS type inverted microscope (Japanese Olympus company), vertical pressure steam sterilizer (Shanghai Bo Xun Industrial Co., Ltd.), cell counting count board (Shanghai precision instrument company), ultrapure water water purifior (Britain PURELABulTRAGENETIC).
Two, test method
1, the cultivation of stomach cancer cell SGC-7901
1.1 cell recovery
(1) from liquid nitrogen container, take out cell cryopreservation tube, be placed in rapidly 37 DEG C ~ 42 DEG C, in 75% alcohol, then move in equality of temperature water-bath; (2) rock l ~ 3min cryopreservation tube gently, frozen storing liquid is melted, move to rapidly in super clean bench; (3) frozen storing liquid containing cell is sucked sterile centrifugation tube, add appropriate RPIM-1640 substratum; (4) put into low speed centrifuge, centrifugal 3 minutes of 800rpm/min after piping and druming mixing, remove supernatant liquor; (5) adding appropriate substratum blows even, is inoculated in 10mL culture dish by cell suspension according to concentration; (6) incubator be placed in containing 5% carbonic acid gas, 37 DEG C of saturated humidities is cultivated.
1.2 passage
(1), when the cell attachment in culture dish about 80%, in super clean bench, cell in several culture dish is blown and beaten, to blow dead cell off with the substratum that pipette, extract is old; (2) suck old substratum with transfer pipet, add appropriate 0.25% trypsin digestion cell, be placed in 30 DEG C of incubators and digest; (3) observe under culture dish being placed in after about 3min inverted microscope, retraction shinny until cell periphery then illustrates that cell departs from from wall after becoming circle; (4) in super clean bench, pancreatin is sucked rapidly.Add appropriate substratum and repeatedly blow and beat cell, make cell depart from culture dish completely; (5) cell suspension is seeded in different culture dish respectively by concentration, supplies substratum; (6) be again placed in containing 5%CO
2, 37 DEG C of saturated humidities incubator in cultivate.
2, cell counting
(1) get out cell counting count board and cover glass, the two is all clean by alcohol wipe, is covered by cover glass on tally; (2) after alcohol volatilization, the appropriate cell suspension of sucking-off, drips at cover glass edge, makes suspension be full of between cover glass and tally, notes the glass guide channel not overflowing cover glass and both sides, counting after leaving standstill; (3) find 4 large lattice under the microscope, each large lattice are divided into again 16 little lattice, count the cell count in 4 large lattice respectively, average.On the left of line ball cytometer and top, on the right side of disregarding and below; (4) average cell number × 10000 of cell concn (individual/mL)=each grid; (5) cell suspension is diluted to experiment desired concn.
3, cell viability measures
(1) SGC-7901 stomach cancer cell suspension 0.9mL to be determined is got; (2) in cell suspension, add trypan blue piping and druming mixing; (3) adopt cell counting count board blind counting at least 200 cells, observe under inverted microscope; (4) Microscopic observation cell dyeing situation, dye light blue person in cell for dead cell, the person of being unstained is viable cell, with the vigor (%) of the per-cent of total cellular score shared by viable cell reflection cell.
4, MTT detects inhibitory rate of cell growth
Experiment grouping: 1. negative control group; 2. compound (I) group 1, compound (I) (50 μm of ol/L); 3. compound (I) group 2, compound (I) (100 μm of ol/L); 4. PDTC group 1, PDTC (50 μm of ol/L); 5. PDTC group 2, PDTC (100 μm of ol/L); 6. drug combination group 1, compound (I) (25 μm of ol/L)+PDTC (25 μm of ol/L); 7. drug combination group 2, compound (I) (50 μm of ol/L)+PDTC (50 μm of ol/L).
(1) the SGC-7901 cell of taking the logarithm vegetative period, with cell counting count board counting, adjustment cell concn is 5 × l0
5/ mL; (2) sample injector is used to be inoculated in 96 orifice plates with every hole 100 μ L.Only be inoculated into 60 middle holes when noting inoculation, periphery 36 hole is filled with PBS, spreads 3 96 orifice plates simultaneously; (3) 96 orifice plates completed are placed in 37 DEG C, 5%CO
2in cell culture incubator, take out after 24h cell attachment; (4) 96 orifice plates are divided into compound (I) group, (0,50,100 μm of ol/L), PDTC group (0,50,100 μm of ol/L), group (0/0,25/25,50/50 μm of ol/L) combined by two medicines, sets up not celliferous blank group (only adding substratum) to give different treatment respectively simultaneously; (5) each concentration of each medicine establishes 5 multiple holes, cultivates 24,48 and 72h respectively; (6) respectively at specific end time point taking-up 96 orifice plate, every hole adds MTT (5g/L) solution 20 μ L, puts back to incubator and continues to cultivate 4h, stop cultivating.(7) carefully suck supernatant liquor in hole, every hole adds 150 μ LDMSO, and plate shaker vibration 10min makes crystallization fully dissolve, and basis of microscopic observation particle disappears.(8) measure optical density(OD) (OD) value in each hole in microplate reader 490nm wavelength place, calculate the inhibitory rate of cell growth of each time point.Inhibiting rate=[1-(dosing group OD value-blank group OD value)/(negative control group OD value-blank group OD value)] × 100%.
5, TUNEL method detects natural death of cerebral cells index
The preparation of 5.1 cell climbing sheets
(1) process of cover glass: cover glass is placed in vitriol oil soaked overnight, next day first with tap water for several times, then be placed in dehydrated alcohol and soak 4h, then clean with deionized water rinsing, be placed on for drying the sterilization of laggard horizontal high voltage in dry case, it is for subsequent use that super clean bench is directly put in taking-up.6 orifice plates are placed in uviolizing 30min in super clean bench; (2) cover glass is placed: after the position preparing to put cover glass in every hole of six orifice plates instills a small amount of substratum, place cover glass again, the tension force making cover glass and orifice plate examine substratum is bonded together, when preventing from adding cell suspension, cover glass hikes up, and causes double-layer cell adherent; (3) the SGC-7901 cell of taking the logarithm vegetative period, cell suspension is blown and beaten in digestion, is l × 10 with cell counting count board adjustment cell concn
6/ mL.(4) add 1mL cell suspension respectively with every hole that sample injector is being placed with cover glass, spread 3 plates simultaneously, be placed in 37 DEG C, 5%CO
2cultivate 24h in incubator and treat cell attachment; In super clean bench, negative control group and experimental group is divided into give different treatment respectively 6 orifice plates after (5) 24 hour cells are adherent, negative control group adds 1mL substratum, experimental group is further divided into compound (I) group, PDTC group and drug combination group 3 subgroups, and every hole adds 1mL medicine.Compound (I) group final concentration be 100 μm of ol/L, PDTC group final concentrations is 100 μm of ol/L, and it is respectively 50 μm of ol/L that two medicines combine that to organize final concentration be two kinds of medicines.Often group establishes 2 multiple holes.(6) 37 DEG C are placed in, 5%CO
2cell culture incubator in continue cultivate.
5.2TUNEL method operation steps
(1) take out 6 orifice plates when 24h is cultivated in cell climbing sheet dosing, carry out following steps successively according to TUNEL specification sheets; (2) supernatant liquor abandoned in every hole is carefully inhaled; (3) each hole adds PBS (4 DEG C) 2mL, and plate shaker rinses 5min × 3 time; (4) every hole adds 1mL precooling cell stationary liquid, and 30min fixed by 4 DEG C of refrigerators.(5) stationary liquid is abandoned in suction, and each hole adds PBS (4 DEG C) 2mL, and plate shaker rinses 5min × 3 time.(6) immerse in confining liquid, room temperature (15 DEG C ~ 25 DEG C) closes 10min.(7) each hole adds PBS (4 DEG C) 2mL, and plate shaker rinses 5min × 3 time.Blot with thieving paper around sample.(8) each sample drips 50 μ LTdT enzyme reaction solutions, 37 DEG C, lucifuge moistening reaction 60min.(9) each hole adds PBS (4 DEG C) 2mL, and plate shaker rinses 5min × 3 time.Blot with thieving paper around sample.(10) 50 μ LStreptavidin-HRP working fluids are dripped, 37 DEG C, lucifuge moistening reaction 30min.(11) each hole adds PBS (4 DEG C) 2mL, and plate shaker rinses 5min × 3 time.(12) 100 μ LDAB working fluids are dripped, color development at room temperature reaction 10min.(13) each hole adds PBS (4 DEG C) 2mL, and plate shaker rinses 5min × 3 time.(14) optical microphotograph Microscopic observation is taken pictures: random selecting 10 high power (× 100) visuals field, and each visual field counts 100 cells, calculates the mean value adjusting index of dying.Apoptotic index (AI)=(positive cell number/total cell count × 100%).The nucleus of positive cell is brown.
6, statistical analysis
Adopt SPSS11.5 to analyze, the measurement data meeting the distribution of JH state, to represent, compares between group and analyzes by Oneway-ANOVA method, and compare between two and adopt LSD-t method, P<0.05 is that difference has statistical significance.
Three, result and conclusion
1, MTT detection of drugs is to the growth inhibition ratio of SGC-7901 stomach cancer cell
MTT is repeated through 3 times, detected result shows, single drug effect is after stomach cancer cell 72h, and the medicine group of 100 μm of ol/L is all higher to the growth inhibition ratio of stomach cancer cell compared with the medicine group of 50 μm of ol/L, and difference has statistical significance (P<0.05).The compound (I) of 50 μm of ol/L is to the growth-inhibiting effect of stomach cancer cell and drug combination 25/25 μm of ol/L group no significant difference (P>0.05).The PDTC of 50 μm of ol/L is to compared with the growth-inhibiting effect of stomach cancer cell and drug combination 25/25 μm of ol/L group, and difference has statistical significance (P<0.05).Drug combination 50/50 μm of ol/L group to the growth inhibition ratio of stomach cancer cell higher than each high density list medicine group (100 μm of ol/L) growth inhibition ratio to stomach cancer cell, difference has statistical significance (P<0.001), in table 1 (* P<0.05, * * P<0.01).
2, TUNEL method detects each group of apoptotic index
Compound (I), PDTC and drug combination group all have the effect of Developing restraint to stomach cancer cell SGC-7901, each group all has statistical significance (P<0.001) with negative control group comparing difference, negative control group has the karyon of a small amount of cell to be dyed to brown, each single medicine group and drug combination group apoptotic cell comparatively all have increase compared with negative control group, the apoptotic index of drug combination group cell is the highest, more remarkable to the inhibition of stomach cancer cell.In table 2 (* * P<0.01).
Conclusion, PDTC and compound (I) two medicine act solely on stomach cancer cell all can the propagation of anticancer, promote the apoptosis of cell, along with the increase of concentration, be enhancing trend to the Developing restraint effect of stomach cancer cell, promote the apoptosis more remarkable effect of stomach cancer cell after two kinds of Drug combinations, all more independent medication group of the growth inhibition ratio of cell and apoptotic index raises.Research find PDTC and the restraining effect of compound (I) two kind of Drug combination to stomach cancer cell more remarkable, and two kinds of medicines are the chemotherapeutics of non-traditional meaning, little to the infringement of body, and avoid the resistance of tumour cell to classic chemotherapy medicine, reference can be provided for the clinical treatment of cancer of the stomach from now on.
Table 1 each medicine group different time points to the growth inhibition ratio of stomach cancer cell (n=5,
)
| Group | n | 24h | 48h | 72h |
| Compound (I) 50 μm of ol/L (1) | 5 | 14.87±5.19 | 16.29±4.53 | 55.70±6.67 |
| Compound (I) 50 μm of ol/L (2) | 5 | 31.00±6.36 | 59.42±7.74 | 74.32±5.84 |
| PDTC50μmol/L(3) | 5 | 24.87±9.04 | 36.83±5.21 | 40.58±7.15 |
| PDTC100μmol/L(4) | 5 | 42.86±6.28 | 44.21±8.44 | 50.31±4.63 |
| Drug combination 25/25 μm of ol/L (5) | 5 | 36.43±8.13 | 38.76±10.87 | 58.55±9.53 |
| Drug combination 50/50 μm of ol/L (6) | 5 | 49.38±2.24 | 74.56±10.59 | 96.12±2.25 |
| F | 17.918 ** | 29.646 ** | 47.625 ** | |
| P(1):(2) | 0.001 | <0.001 | <0.001 | |
| (3):(4) | <0.001 | 0.169 | 0.025 | |
| (5):(6) | 0.005 | <0.001 | <0.001 | |
| (1):(5) | <0.001 | <0.001 | 0.49 | |
| (3):(5) | 0.01 | 0.713 | <0.001 | |
| (2):(6) | <0.001 | 0.008 | <0.001 | |
| (4):(6) | 0.13 | <0.001 | <0.001 |
After table 2 drug effect 24h each group cell apoptotic index (n=3,
)
Embodiment 3
The preparation of tablet: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, vehicle is added, pelletizing press sheet than the ratio for 1:9 in itself and excipient weight.
Embodiment 4
Prepared by oral liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, oral liquid method for making makes oral liquid routinely.
Embodiment 5
The preparation of capsule or granule: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, add vehicle in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 6
The preparation of injection liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, inject with water routinely, essence filter, injection liquid is made in embedding sterilizing.
Embodiment 7
The preparation of aseptic powder injection: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, be dissolved in sterile water for injection, stirring makes molten, filter with aseptic suction funnel, aseptic essence filter again, be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains powder injection.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (7)
1. there is the compound (I) of following structural formula,
2. the preparation method of compound according to claim 1 (I), it is characterized in that comprising following operation steps: the dry mature fruit of Sharpleaf Galangal Fruit is pulverized by (a), extract with 80 ~ 90% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 15% ethanol elution, 8 column volumes, then use 75% ethanol elution, 12 column volumes, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract; C in () step (b), 75% ethanol elution thing medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 85:1,55:1,35:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 20:1,15:1 and 10:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 80%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
3. the preparation method of compound according to claim 2 (I), is characterized in that: in step (a), extracts, united extraction liquid with 85% alcohol heat reflux.
4. the preparation method of compound according to claim 2 (I), is characterized in that: described macroporous resin is AB-8 type macroporous adsorbent resin.
5. a pharmaceutical composition, is characterized in that: this pharmaceutical composition contains the compound according to claim 1 (I) for the treatment of significant quantity and pharmaceutically acceptable carrier.
6. the application of compound according to claim 1 (I) in the medicine of preparation treatment cancer of the stomach.
7. the application of pharmaceutical composition according to claim 5 in the medicine of preparation treatment cancer of the stomach.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510830702.7A CN105254502A (en) | 2015-11-25 | 2015-11-25 | New diterpenoid compound and preparation method and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510830702.7A CN105254502A (en) | 2015-11-25 | 2015-11-25 | New diterpenoid compound and preparation method and medical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105254502A true CN105254502A (en) | 2016-01-20 |
Family
ID=55094499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510830702.7A Pending CN105254502A (en) | 2015-11-25 | 2015-11-25 | New diterpenoid compound and preparation method and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105254502A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110585385A (en) * | 2019-10-17 | 2019-12-20 | 郑州大学第一附属医院 | Extraction method and qualitative analysis method of alpinia oxyphylla sesquiterpenoids |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103721148A (en) * | 2012-10-10 | 2014-04-16 | 海南医学院 | Sharpleaf galangal fruit composition for treatment of acute or chronic gastroenteritis and preparation method thereof |
| CN105175265A (en) * | 2015-10-19 | 2015-12-23 | 淄博夸克医药技术有限公司 | Novel diterpenoid compound for treating liver cancer |
-
2015
- 2015-11-25 CN CN201510830702.7A patent/CN105254502A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103721148A (en) * | 2012-10-10 | 2014-04-16 | 海南医学院 | Sharpleaf galangal fruit composition for treatment of acute or chronic gastroenteritis and preparation method thereof |
| CN105175265A (en) * | 2015-10-19 | 2015-12-23 | 淄博夸克医药技术有限公司 | Novel diterpenoid compound for treating liver cancer |
Non-Patent Citations (3)
| Title |
|---|
| TOSHIO MORIKAWA ET AL.: "Absolute Stereostructures of Three New Sesquiterpenes from the Fruit of Alpinia oxyphylla with Inhibitory Effects on Nitric Oxide Production and Degranulation in RBL-2H3 Cells", 《J. NAT. PROD.》 * |
| YE,TIAN ET AL.: "Diterpenoids with Diverse Skeletons from the Roots of Euphorbia micractina", 《JOURNAL OF NATURAL PRODUCTS》 * |
| 陈萍等: "益智仁的化学成分及药理活性研究进展", 《现代药物与临床》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110585385A (en) * | 2019-10-17 | 2019-12-20 | 郑州大学第一附属医院 | Extraction method and qualitative analysis method of alpinia oxyphylla sesquiterpenoids |
| CN110585385B (en) * | 2019-10-17 | 2021-08-17 | 郑州大学第一附属医院 | Extraction method and qualitative analysis method of alpinia oxyphylla sesquiterpenoids |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105085539A (en) | Novel diterpenoid compound, preparation method thereof and medical application | |
| CN105198893A (en) | Diterpenoid compounds for treating stomach cancer | |
| CN105017276A (en) | Five-membered epoxy structure compound for treating pancreatic cancer | |
| CN104974145A (en) | Diterpene lactone compounds, pharmaceutical composition containing compounds, and preparation method and application thereof | |
| CN105085452A (en) | Sesquiterpene naphthoquinone compound as well as preparation method and medical application thereof | |
| CN105943532A (en) | Application of diterpenoid compound to preparation of medicament for treating liver cancer | |
| CN105175265A (en) | Novel diterpenoid compound for treating liver cancer | |
| CN105111080A (en) | Novel diterpene compound and medical application thereof | |
| CN105294665A (en) | Novel diterpene compound for neuroprotection | |
| CN105384750A (en) | Kauran diterpene compound for curing renal cancer | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN105418545A (en) | Novel isocoumarin compound and preparation method and medical application thereof | |
| CN105524075A (en) | A novel diterpene compound, a preparing method thereof and medical uses of the diterpene compound | |
| CN105198896A (en) | Clerodane diterpenoid compound and preparation method and medical application thereof | |
| CN105348223A (en) | Novel sesquiterpenoid and preparation method and medical application thereof | |
| CN105367536A (en) | Novel iridoid and preparation method and medical application thereof | |
| CN105418539A (en) | New meroterpenoid compound as well as preparation method and pharmaceutical application thereof | |
| CN105198844A (en) | Novel limonin compound as well as preparation method and medical application thereof | |
| CN105198897A (en) | New kaurane diterpenoid compound, preparation method and medical application of compound in treating liver cancer | |
| CN105622629A (en) | Kaurane type diterpenoid compound for treating prostatic cancer | |
| CN105348227A (en) | Novel isocoumarins compound as well as preparation method and medical application thereof | |
| CN106074499A (en) | The application in medicine of a kind of Crow alkane type diterpene-kind compound | |
| CN105523937A (en) | Diterpene compound with medical application and preparation method thereof | |
| CN105481810A (en) | Novel Fumu lactone compounds, and preparation method and medical application thereof | |
| CN105481876A (en) | Diterpene compound for treating ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160120 |